Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Genomic Health, Inc.    GHDX

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/19/2017 07/20/2017 07/21/2017 07/24/2017 07/25/2017 Date
33.27(c) 33.22(c) 32.94(c) 33.04(c) 32.94 Last
100 744 73 654 77 900 63 089 6 441 Volume
-0.51% -0.15% -0.84% +0.30% -0.30% Change
More quotes
Financials ($)
Sales 2017 356 M
EBIT 2017 -1,27 M
Net income 2017 0,28 M
Finance 2017 53,3 M
Yield 2017 -
Sales 2018 392 M
EBIT 2018 12,9 M
Net income 2018 10,6 M
Finance 2018 70,4 M
Yield 2018 -
P/E ratio 2017 1 720,83
P/E ratio 2018 101,66
EV / Sales2017 3,04x
EV / Sales2018 2,71x
Capitalization 1 135 M
More Financials
Company
Genomic Health, Inc. engages in the development and global commercialization of genomic- based clinical laboratory services that analyze the underlying biology of cancers, allowing physicians and patients to make individualized treatment decisions.Its uses a platform which translates a massive... 
More about the company
Surperformance© ratings of Genomic Health, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on GENOMIC HEALTH, INC.
07/22 INSIDER TRADING ACTIVITY GENOMIC HEA : GHDX) – insider Sold 3,174 shares o..
07/20 GENOMIC HEALTH : to Announce Second Quarter 2017 Financial Results and Host Conf..
07/12 GENOMIC HEALTH : Updated St. Gallen International Breast Cancer Guidelines Reinf..
06/19 GENOMIC HEALTH INC : Submission of Matters to a Vote of Security Holders (form 8..
06/09 GENOMIC HEALTH : Presents Data Further Demonstrating Ability of Oncotype DX® Tes..
06/02 GENOMIC HEALTH : Presents Data Further Demonstrating Ability of Oncotype DX® Tes..
05/31 GENOMIC HEALTH : Announces Presentation of Eight Oncotype DX Studies at the 2017..
05/30 GENOMIC HEALTH : Announces Presentation of Eight Oncotype DX® Studies at the 201..
05/25 GENOMIC HEALTH : Prospective Oncotype DX® Genomic Prostate Score Test Data Prese..
05/25 GENOMIC HEALTH : Oncotype DX® Genomic Prostate Score GPS Test Predicts 10-year R..
More news
Sector news : Biotechnology & Medical Research - NEC
01:37pDJELI LILLY AND : to Delay Arthritis Drug Application -- Market Talk
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
07/12 FDA panel backs Novartis' pioneering new cancer gene therapy
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
07/20Genomic Health to Announce Second Quarter 2017 Financial Results and Host Con.. 
07/16Zacks: Brokerages Anticipate Genomic Health, Inc. $GHDX Will Post Quarterly S.. 
07/09Swiss National Bank Continues to Hold Stake in Genomic Health, Inc. $GHDX  
07/05Renaissance Technologies LLC Has $23.09 Million Stake in Genomic Health, Inc... 
07/03Get the latest ratings for $GHDX $SNAP $SPWRA $BDREF $ESEA in your inbox with.. 
More tweets
Qtime:25
News from SeekingAlpha
06/27 If You Like Illumina, You'll Love Genomic Health
05/13 Genomic Health's (GHDX) CEO Kim Popovits on Q1 2017 Results - Earnings Call T..
05/09 Genomic Health beats by $0.05, misses on revenue
05/08 Notable earnings after Tuesday?s close
05/05 Genomic Health updates on Oncotype DX Genomic Prostate Score
Chart GENOMIC HEALTH, INC.
Duration : Period :
Genomic Health, Inc. Technical Analysis Chart | GHDX | US37244C1018 | 4-Traders
Technical analysis trends GENOMIC HEALTH, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 32,2 $
Spread / Average Target -2,5%
EPS Revisions
Managers
NameTitle
Kimberly J. Popovits Chairman, President & Chief Executive Officer
G. Bradley Cole COO, CFO & Principal Accounting Officer
Steven Shak Chief Scientific Officer
Phillip G. Febbo Chief Medical Officer
Michael Vedda Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
GENOMIC HEALTH, INC.12.42%1 135
INCYTE CORPORATION33.86%28 314
QUINTILES IMS HOLDINGS INC19.86%19 795
LONZA GROUP31.59%16 758
CELLTRION, INC.--.--%12 650
ALKERMES PLC5.49%8 982